Handelsbanken Fonder AB Sells 212,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Handelsbanken Fonder AB decreased its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 55.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 168,000 shares of the company’s stock after selling 212,000 shares during the quarter. Handelsbanken Fonder AB’s holdings in Structure Therapeutics were worth $4,704,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. State of Wyoming purchased a new position in Structure Therapeutics during the 2nd quarter valued at $28,000. EverSource Wealth Advisors LLC lifted its position in shares of Structure Therapeutics by 530.0% during the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares during the last quarter. Assetmark Inc. lifted its position in shares of Structure Therapeutics by 39.9% during the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after purchasing an additional 820 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Structure Therapeutics by 29.1% during the second quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after purchasing an additional 994 shares during the period. Finally, ANTIPODES PARTNERS Ltd grew its holdings in shares of Structure Therapeutics by 39.1% in the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after purchasing an additional 1,146 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on GPCR. BMO Capital Markets reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, January 6th. Guggenheim raised their target price on shares of Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. JPMorgan Chase & Co. lifted their price target on shares of Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. Citigroup reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Friday, December 12th. Finally, Jefferies Financial Group set a $125.00 target price on Structure Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $107.90.

Structure Therapeutics Stock Performance

Shares of GPCR opened at $62.90 on Tuesday. The company has a 50 day moving average price of $75.40 and a 200-day moving average price of $47.24. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $13.22 and a fifty-two week high of $94.90. The stock has a market capitalization of $4.44 billion, a PE ratio of -79.62 and a beta of -1.79.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). Equities research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.